The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global High Blood Pressure Drugs (Hypertension) Market Research Report 2025
Synopsis
The global High Blood Pressure Drugs (Hypertension) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for High Blood Pressure Drugs (Hypertension), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High Blood Pressure Drugs (Hypertension).
Report Scope
The High Blood Pressure Drugs (Hypertension) market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global High Blood Pressure Drugs (Hypertension) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the High Blood Pressure Drugs (Hypertension) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
Bayer
Symplmed
Novartis
Merck
Sanofi
Boryung
Reata Pharmaceuticals
Lung Biotechnology
Yuhan
Takeda
Alvogen
Segment by Type
ACEI
CCB
ARB
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of High Blood Pressure Drugs (Hypertension) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of High Blood Pressure Drugs (Hypertension) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global High Blood Pressure Drugs (Hypertension) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for High Blood Pressure Drugs (Hypertension), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High Blood Pressure Drugs (Hypertension).
Report Scope
The High Blood Pressure Drugs (Hypertension) market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global High Blood Pressure Drugs (Hypertension) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the High Blood Pressure Drugs (Hypertension) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
Bayer
Symplmed
Novartis
Merck
Sanofi
Boryung
Reata Pharmaceuticals
Lung Biotechnology
Yuhan
Takeda
Alvogen
Segment by Type
ACEI
CCB
ARB
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of High Blood Pressure Drugs (Hypertension) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of High Blood Pressure Drugs (Hypertension) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 High Blood Pressure Drugs (Hypertension) Market Overview
1.1 Product Overview and Scope of High Blood Pressure Drugs (Hypertension)
1.2 High Blood Pressure Drugs (Hypertension) Segment by Type
1.2.1 Global High Blood Pressure Drugs (Hypertension) Market Value Comparison by Type (2024-2030)
1.2.2 ACEI
1.2.3 CCB
1.2.4 ARB
1.3 High Blood Pressure Drugs (Hypertension) Segment by Application
1.3.1 Global High Blood Pressure Drugs (Hypertension) Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global High Blood Pressure Drugs (Hypertension) Market Size Estimates and Forecasts
1.4.1 Global High Blood Pressure Drugs (Hypertension) Revenue 2019-2030
1.4.2 Global High Blood Pressure Drugs (Hypertension) Sales 2019-2030
1.4.3 Global High Blood Pressure Drugs (Hypertension) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 High Blood Pressure Drugs (Hypertension) Market Competition by Manufacturers
2.1 Global High Blood Pressure Drugs (Hypertension) Sales Market Share by Manufacturers (2019-2024)
2.2 Global High Blood Pressure Drugs (Hypertension) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global High Blood Pressure Drugs (Hypertension) Average Price by Manufacturers (2019-2024)
2.4 Global High Blood Pressure Drugs (Hypertension) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of High Blood Pressure Drugs (Hypertension), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of High Blood Pressure Drugs (Hypertension), Product Type & Application
2.7 High Blood Pressure Drugs (Hypertension) Market Competitive Situation and Trends
2.7.1 High Blood Pressure Drugs (Hypertension) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest High Blood Pressure Drugs (Hypertension) Players Market Share by Revenue
2.7.3 Global High Blood Pressure Drugs (Hypertension) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 High Blood Pressure Drugs (Hypertension) Retrospective Market Scenario by Region
3.1 Global High Blood Pressure Drugs (Hypertension) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global High Blood Pressure Drugs (Hypertension) Global High Blood Pressure Drugs (Hypertension) Sales by Region: 2019-2030
3.2.1 Global High Blood Pressure Drugs (Hypertension) Sales by Region: 2019-2024
3.2.2 Global High Blood Pressure Drugs (Hypertension) Sales by Region: 2025-2030
3.3 Global High Blood Pressure Drugs (Hypertension) Global High Blood Pressure Drugs (Hypertension) Revenue by Region: 2019-2030
3.3.1 Global High Blood Pressure Drugs (Hypertension) Revenue by Region: 2019-2024
3.3.2 Global High Blood Pressure Drugs (Hypertension) Revenue by Region: 2025-2030
3.4 North America High Blood Pressure Drugs (Hypertension) Market Facts & Figures by Country
3.4.1 North America High Blood Pressure Drugs (Hypertension) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America High Blood Pressure Drugs (Hypertension) Sales by Country (2019-2030)
3.4.3 North America High Blood Pressure Drugs (Hypertension) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe High Blood Pressure Drugs (Hypertension) Market Facts & Figures by Country
3.5.1 Europe High Blood Pressure Drugs (Hypertension) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe High Blood Pressure Drugs (Hypertension) Sales by Country (2019-2030)
3.5.3 Europe High Blood Pressure Drugs (Hypertension) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific High Blood Pressure Drugs (Hypertension) Market Facts & Figures by Country
3.6.1 Asia Pacific High Blood Pressure Drugs (Hypertension) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific High Blood Pressure Drugs (Hypertension) Sales by Country (2019-2030)
3.6.3 Asia Pacific High Blood Pressure Drugs (Hypertension) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America High Blood Pressure Drugs (Hypertension) Market Facts & Figures by Country
3.7.1 Latin America High Blood Pressure Drugs (Hypertension) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America High Blood Pressure Drugs (Hypertension) Sales by Country (2019-2030)
3.7.3 Latin America High Blood Pressure Drugs (Hypertension) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa High Blood Pressure Drugs (Hypertension) Market Facts & Figures by Country
3.8.1 Middle East and Africa High Blood Pressure Drugs (Hypertension) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa High Blood Pressure Drugs (Hypertension) Sales by Country (2019-2030)
3.8.3 Middle East and Africa High Blood Pressure Drugs (Hypertension) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global High Blood Pressure Drugs (Hypertension) Sales by Type (2019-2030)
4.1.1 Global High Blood Pressure Drugs (Hypertension) Sales by Type (2019-2024)
4.1.2 Global High Blood Pressure Drugs (Hypertension) Sales by Type (2025-2030)
4.1.3 Global High Blood Pressure Drugs (Hypertension) Sales Market Share by Type (2019-2030)
4.2 Global High Blood Pressure Drugs (Hypertension) Revenue by Type (2019-2030)
4.2.1 Global High Blood Pressure Drugs (Hypertension) Revenue by Type (2019-2024)
4.2.2 Global High Blood Pressure Drugs (Hypertension) Revenue by Type (2025-2030)
4.2.3 Global High Blood Pressure Drugs (Hypertension) Revenue Market Share by Type (2019-2030)
4.3 Global High Blood Pressure Drugs (Hypertension) Price by Type (2019-2030)
5 Segment by Application
5.1 Global High Blood Pressure Drugs (Hypertension) Sales by Application (2019-2030)
5.1.1 Global High Blood Pressure Drugs (Hypertension) Sales by Application (2019-2024)
5.1.2 Global High Blood Pressure Drugs (Hypertension) Sales by Application (2025-2030)
5.1.3 Global High Blood Pressure Drugs (Hypertension) Sales Market Share by Application (2019-2030)
5.2 Global High Blood Pressure Drugs (Hypertension) Revenue by Application (2019-2030)
5.2.1 Global High Blood Pressure Drugs (Hypertension) Revenue by Application (2019-2024)
5.2.2 Global High Blood Pressure Drugs (Hypertension) Revenue by Application (2025-2030)
5.2.3 Global High Blood Pressure Drugs (Hypertension) Revenue Market Share by Application (2019-2030)
5.3 Global High Blood Pressure Drugs (Hypertension) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly High Blood Pressure Drugs (Hypertension) Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer High Blood Pressure Drugs (Hypertension) Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bayer High Blood Pressure Drugs (Hypertension) Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Symplmed
6.4.1 Symplmed Corporation Information
6.4.2 Symplmed Description and Business Overview
6.4.3 Symplmed High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Symplmed High Blood Pressure Drugs (Hypertension) Product Portfolio
6.4.5 Symplmed Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis High Blood Pressure Drugs (Hypertension) Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Merck High Blood Pressure Drugs (Hypertension) Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi High Blood Pressure Drugs (Hypertension) Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Boryung
6.8.1 Boryung Corporation Information
6.8.2 Boryung Description and Business Overview
6.8.3 Boryung High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Boryung High Blood Pressure Drugs (Hypertension) Product Portfolio
6.8.5 Boryung Recent Developments/Updates
6.9 Reata Pharmaceuticals
6.9.1 Reata Pharmaceuticals Corporation Information
6.9.2 Reata Pharmaceuticals Description and Business Overview
6.9.3 Reata Pharmaceuticals High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Reata Pharmaceuticals High Blood Pressure Drugs (Hypertension) Product Portfolio
6.9.5 Reata Pharmaceuticals Recent Developments/Updates
6.10 Lung Biotechnology
6.10.1 Lung Biotechnology Corporation Information
6.10.2 Lung Biotechnology Description and Business Overview
6.10.3 Lung Biotechnology High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Lung Biotechnology High Blood Pressure Drugs (Hypertension) Product Portfolio
6.10.5 Lung Biotechnology Recent Developments/Updates
6.11 Yuhan
6.11.1 Yuhan Corporation Information
6.11.2 Yuhan High Blood Pressure Drugs (Hypertension) Description and Business Overview
6.11.3 Yuhan High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Yuhan High Blood Pressure Drugs (Hypertension) Product Portfolio
6.11.5 Yuhan Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda High Blood Pressure Drugs (Hypertension) Description and Business Overview
6.12.3 Takeda High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Takeda High Blood Pressure Drugs (Hypertension) Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Alvogen
6.13.1 Alvogen Corporation Information
6.13.2 Alvogen High Blood Pressure Drugs (Hypertension) Description and Business Overview
6.13.3 Alvogen High Blood Pressure Drugs (Hypertension) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Alvogen High Blood Pressure Drugs (Hypertension) Product Portfolio
6.13.5 Alvogen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 High Blood Pressure Drugs (Hypertension) Industry Chain Analysis
7.2 High Blood Pressure Drugs (Hypertension) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 High Blood Pressure Drugs (Hypertension) Production Mode & Process
7.4 High Blood Pressure Drugs (Hypertension) Sales and Marketing
7.4.1 High Blood Pressure Drugs (Hypertension) Sales Channels
7.4.2 High Blood Pressure Drugs (Hypertension) Distributors
7.5 High Blood Pressure Drugs (Hypertension) Customers
8 High Blood Pressure Drugs (Hypertension) Market Dynamics
8.1 High Blood Pressure Drugs (Hypertension) Industry Trends
8.2 High Blood Pressure Drugs (Hypertension) Market Drivers
8.3 High Blood Pressure Drugs (Hypertension) Market Challenges
8.4 High Blood Pressure Drugs (Hypertension) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
